Results from the Phase 3 TRIDENT trial showed that starting Tumor Treating Fields (TTFields) at the beginning of chemoradiotherapy did not significantly improve overall survival compared with starting the therapy during the standard maintenance phase for patients with newly diagnosed glioblastoma.
The study enrolled 981 patients who received TTFields either alongside radiation and temozolomide chemotherapy or after chemoradiotherapy was completed. Median overall survival was 17.7 months in the early-start group and 17.5 months in the standard-start group. One-, two-, and three-year survival rates were also similar between the groups.
Although the trial did not meet its primary endpoint, both treatment arms achieved encouraging long-term survival outcomes. Early use of TTFields was found to be safe and feasible, with no new safety concerns reported. Side effects were consistent with previous studies.
Researchers noted that about one-quarter of patients never reached the maintenance phase, highlighting the importance of evaluating earlier treatment strategies.